We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+26.9%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$1.05B
AUM Growth
+$91.8M
Cap. Flow
-$24.1M
Cap. Flow %
-2.3%
Top 10 Hldgs %
32.3%
Holding
111
New
20
Increased
23
Reduced
56
Closed
11

Top Buys

Rank Stock Value
1
MASI
Masimo
MASI
+$28.6M
2
DXCM icon
DexCom
DXCM
+$26.9M
3
EYPT icon
EyePoint Inc
EYPT
+$15.4M
4
WAT icon
Waters Corp
WAT
+$15.4M
5
MTD icon
Mettler-Toledo International
MTD
+$15.3M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$17.7M
2
BIIB icon
Biogen
BIIB
+$15.5M
3
DHR icon
Danaher
DHR
+$11.4M
4
CSTL icon
Castle Biosciences
CSTL
+$10.5M
5
VRDN icon
Viridian Therapeutics
VRDN
+$10M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNKD icon
76
MannKind Corp
MNKD
$1.24B
$3.63M 0.35%
640,356
-15,728
-2% -$86.6K
CAI
77
Caris Life Sciences
CAI
$6.29B
$3.37M 0.32%
+125,000
New +$3.52M
TVTX icon
78
Travere Therapeutics
TVTX
$5.86B
$3.3M 0.31%
86,297
-253,467
-75% -$8.24M
CERT icon
79
Certara
CERT
$1.22B
$3.07M 0.29%
348,750
-203,100
-37% -$2.09M
ANNX icon
80
Annexon
ANNX
$873M
$3.02M 0.29%
601,202
+195,249
+48% +$746K
CVRX icon
81
CVRx
CVRX
$72.7M
$2.93M 0.28%
413,018
-78,390
-16% -$716K
AGIO icon
82
Agios Pharmaceuticals
AGIO
$2.04B
$2.71M 0.26%
99,604
-776
-0.8% -$27.2K
SLDB icon
83
Solid Biosciences
SLDB
$971M
$2.36M 0.22%
418,371
+21,975
+6% +$119K
PTGX icon
84
Protagonist Therapeutics
PTGX
$9.84B
$2.27M 0.22%
25,973
-35,876
-58% -$2.94M
QTRX icon
85
Quanterix
QTRX
$139M
$2.09M 0.2%
328,956
+76,745
+30% +$477K
LUNG icon
86
Pulmonx
LUNG
$98.4M
$1.61M 0.15%
727,781
+227,119
+45% +$427K
RARE icon
87
Ultragenyx Pharmaceutical
RARE
$2.65B
$1.43M 0.14%
62,030
-6,606
-10% -$217K
ACHC icon
88
Acadia Healthcare
ACHC
$2.95B
$1.42M 0.14%
+100,000
New +$1.89M
INSP icon
89
Inspire Medical Systems
INSP
$1.68B
$1.38M 0.13%
+15,000
New +$1.44M
SENS icon
90
Senseonics Holdings Inc
SENS
$419M
$1.14M 0.11%
+206,793
New +$1.44M
CRNX icon
91
Crinetics Pharmaceuticals
CRNX
$8.96B
$1.06M 0.1%
22,852
-50,873
-69% -$2.26M
RPID icon
92
Rapid Micro Biosystems
RPID
$84.8M
$1.03M 0.1%
354,465
-558,978
-61% -$1.94M
MDLN
93
Medline Inc
MDLN
$31.1B
$863K 0.08%
+20,558
New +$868K
ARAY icon
94
Accuray
ARAY
$33.4M
$703K 0.07%
+852,012
New +$1.06M
CMPS
95
Compass Pathways
CMPS
$1.97B
$686K 0.07%
99,472
-528
-0.5% -$3.22K
ENTX icon
96
Entera Bio
ENTX
$138M
$534K 0.05%
275,073
-5,749
-2% -$13.5K
FOCL
97
EDAP TMS S.A.
FOCL
$178M
$509K 0.05%
154,832
– –
TMCI icon
98
Treace Medical Concepts
TMCI
$309M
$489K 0.05%
199,393
-648,282
-76% -$2.82M
BFLY icon
99
Butterfly Network
BFLY
$2.52B
$383K 0.04%
100,835
-501,357
-83% -$1.36M
OVID icon
100
Ovid Therapeutics
OVID
$489M
$328K 0.03%
201,036
-1,942
-1% -$2.99K
1 2 3
4
5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Parkman Healthcare Partners held 111 positions worth $1.05B, up 9.6% from $959M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Parkman Healthcare Partners's Q4 2025 filing shows 20 new, 23 increased, 56 reduced and 11 closed positions. Its largest new stake was Masimo: 200,000 shares worth $26M. The largest sale was Alnylam Pharmaceuticals, an estimated $17.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.

  • Parkman Healthcare Partners's largest Q4 2025 buy was Masimo: 200,000 shares worth $26M.
  • Parkman Healthcare Partners added most to DexCom in Q4 2025, an estimated $26.9M increase.
  • Parkman Healthcare Partners's biggest Q4 2025 reduction was Alnylam Pharmaceuticals, cutting an estimated $17.7M.
  • Parkman Healthcare Partners fully exited United Therapeutics in Q4 2025, selling an estimated $9.22M.
  • Parkman Healthcare Partners's ten largest holdings make up 32% of its $1.05B portfolio in Q4 2025.
  • Parkman Healthcare Partners opened 20 new positions and closed 11 in Q4 2025.
  • Parkman Healthcare Partners's portfolio value rose 9.6% quarter-over-quarter to $1.05B.

Based on Parkman Healthcare Partners's 13F filing for Q4 2025, filed 17 Feb 2026.